ATE485366T1 - Verwendung von lysyloxydase inhibitoren zur zellkultur und gewebeaufbau - Google Patents

Verwendung von lysyloxydase inhibitoren zur zellkultur und gewebeaufbau

Info

Publication number
ATE485366T1
ATE485366T1 AT02772482T AT02772482T ATE485366T1 AT E485366 T1 ATE485366 T1 AT E485366T1 AT 02772482 T AT02772482 T AT 02772482T AT 02772482 T AT02772482 T AT 02772482T AT E485366 T1 ATE485366 T1 AT E485366T1
Authority
AT
Austria
Prior art keywords
cell culture
inhibitors
lysyloxydase
tissue construction
tissue
Prior art date
Application number
AT02772482T
Other languages
English (en)
Inventor
Jean Farjanel
Nee Baudoux Odile Damour
Pascal Sommer
Fabienne Braye
Michel-Henri Fessy
Original Assignee
Centre Nat Rech Scient
Univ Claude Bernard Lyon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Univ Claude Bernard Lyon filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE485366T1 publication Critical patent/ATE485366T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3817—Cartilage-forming cells, e.g. pre-chondrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3633—Extracellular matrix [ECM]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
    • A61L27/3645—Connective tissue
    • A61L27/3654—Cartilage, e.g. meniscus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3843—Connective tissue
    • A61L27/3852—Cartilage, e.g. meniscus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
    • C12N5/0698—Skin equivalents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/71—Oxidoreductases (EC 1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/09—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells
    • C12N2502/094—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells keratinocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1323—Adult fibroblasts

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02772482T 2001-08-03 2002-08-02 Verwendung von lysyloxydase inhibitoren zur zellkultur und gewebeaufbau ATE485366T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0110443A FR2828206B1 (fr) 2001-08-03 2001-08-03 Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
PCT/FR2002/002789 WO2003014333A1 (fr) 2001-08-03 2002-08-02 Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire

Publications (1)

Publication Number Publication Date
ATE485366T1 true ATE485366T1 (de) 2010-11-15

Family

ID=8866275

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02772482T ATE485366T1 (de) 2001-08-03 2002-08-02 Verwendung von lysyloxydase inhibitoren zur zellkultur und gewebeaufbau

Country Status (9)

Country Link
US (1) US20040248871A1 (de)
EP (1) EP1412484B1 (de)
JP (1) JP4733346B2 (de)
AT (1) ATE485366T1 (de)
CA (1) CA2456271C (de)
DE (1) DE60238058D1 (de)
ES (1) ES2351875T3 (de)
FR (1) FR2828206B1 (de)
WO (1) WO2003014333A1 (de)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
FR2855968B1 (fr) 2003-06-13 2012-11-30 Coletica Stimulation de la synthese et de l'activite d'une isoforme de la lysyl oxydase-like loxl pour stimuler la formation de fibres elastiques
WO2005069975A2 (en) 2004-01-23 2005-08-04 Massachusetts Eye & Ear Infirmary Lysyl oxidase-like 1 (loxl1) and elastogenesis
US20070225242A1 (en) * 2005-06-21 2007-09-27 The Board Of Trustees Of The Leland Stanford Junior University Method and composition for treating and preventing tumor metastasis in vivo
US20070021365A1 (en) * 2005-06-21 2007-01-25 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of Lysyl oxidase for treating tumor growth and diagnostics relating thereto
US7834153B2 (en) * 2006-06-05 2010-11-16 University Of South Florida Combination of insulin and ascorbate to enhance wound healing
WO2007145934A1 (en) * 2006-06-05 2007-12-21 University Of South Florida Combination of insulin and ascorbate to enhance wound healing
US9125856B1 (en) * 2006-12-06 2015-09-08 The Trustees Of Columbia University In The City Of New York Method of stabilizing human eye tissue
CA2693310C (en) 2007-08-02 2018-11-27 Arresto Biosciences, Inc. Lox and loxl2 inhibitors, antibodies and uses thereof
FR2927632B1 (fr) * 2008-02-14 2013-07-19 Basf Beauty Care Solutions F Cornee et muqueuse reconstruites.
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
KR20110140121A (ko) * 2009-02-06 2011-12-30 길리아드 바이오로직스, 인크. 혈관신생의 치료를 위한 방법 및 조성물
CA2771702A1 (en) 2009-08-21 2011-02-24 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and loxl2
BR112012019693A2 (pt) 2010-02-04 2017-06-20 Gilead Biologics Inc anticorpos que se ligam à lisil oxidase-like 2 (loxl2) e métodos de uso para eles.
US20140186340A1 (en) 2011-04-08 2014-07-03 Gilead Biologics, Inc. Methods and Compositions for Normalization of Tumor Vasculature by Inhibition of LOXL2
TW201441216A (zh) 2012-12-21 2014-11-01 Gilead Calistoga Llc 肌醇磷酯３－激酶的抑制劑
US9029384B2 (en) 2012-12-21 2015-05-12 Gilead Calistoga, LLC. Phosphatidylinositol 3-kinase inhibitors
ES2667173T3 (es) 2013-06-14 2018-05-09 Gilead Calistoga Llc Inhibidores de fosfatidilinositol 3-quinasa
WO2015081127A2 (en) 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
EP3083630B1 (de) 2013-12-20 2019-08-21 Gilead Calistoga LLC Prozessverfahren für phosphatidylinositol-3-kinase-hemmer
JP2017500319A (ja) 2013-12-20 2017-01-05 ギリアード カリストガ エルエルシー （ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの塩酸塩の多形形態
AU2015206194A1 (en) 2014-01-20 2016-07-28 Gilead Sciences, Inc. Therapies for treating cancers
EA201692202A1 (ru) 2014-06-11 2017-06-30 Джилид Сайэнс, Инк. Способы лечения сердечно-сосудистых заболеваний
TWI681954B (zh) 2014-06-12 2020-01-11 美商西爾拉癌症醫學公司 Ｎ-（氰基甲基）-４-（２-（４-𠰌啉基苯基胺基）嘧啶-４-基）苯甲醯胺
US11021467B2 (en) 2014-06-13 2021-06-01 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
CA2952044C (en) 2014-06-13 2019-01-29 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
TW201639573A (zh) 2015-02-03 2016-11-16 吉李德科學股份有限公司 有關治療癌症之合併治療
SG11201606876RA (en) 2015-03-04 2016-10-28 Gilead Sciences Inc Toll like receptor modulator compounds
JP6785804B2 (ja) 2015-06-23 2020-11-18 ギリアド サイエンシズ， インコーポレイテッド Ｂ細胞悪性腫瘍を治療するための組合せ療法
JP2019510752A (ja) 2016-03-04 2019-04-18 ギリアード サイエンシーズ， インコーポレイテッド オートタキシン阻害剤の組成物及び合剤
JP2019513737A (ja) 2016-04-08 2019-05-30 ギリアード サイエンシーズ， インコーポレイテッド がん、炎症性疾患および自己免疫疾患を処置するための組成物および方法
US10059769B2 (en) 2016-06-13 2018-08-28 I-Mab Anti-PD-L1 antibodies and uses thereof
MA45848A (fr) 2016-08-04 2019-06-12 Gilead Sciences Inc Cobicistat destiné à être utilisé dans des traitements du cancer
SI3507276T1 (sl) 2016-09-02 2022-01-31 Gilead Sciences, Inc. Spojine modulatorja toličnih receptorjev
WO2018045150A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2018057808A1 (en) 2016-09-23 2018-03-29 Gilead Sciences, Inc. Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors
WO2018085069A1 (en) 2016-11-03 2018-05-11 Gilead Sciences, Inc. Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer
WO2018097977A1 (en) 2016-11-22 2018-05-31 Gilead Sciences, Inc. Crystalline forms of a phosphate complex of a bet inhibitor
CA3045376C (en) 2017-01-24 2022-08-30 I-Mab Anti-cd73 antibodies and uses thereof
US10370381B2 (en) 2017-02-24 2019-08-06 Gilead Sciences, Inc. Inhibitors of bruton'S tyrosine kinase
US10314844B2 (en) 2017-02-24 2019-06-11 Gilead Sciences, Inc. Inhibitors of Bruton's tyrosine kinase
WO2019018892A1 (en) 2017-07-26 2019-01-31 The University Of Queensland COMPOUNDS CONTAINING DISULFIDE BOND AND USES THEREOF
KR102891807B1 (ko) 2017-08-22 2025-12-01 길리애드 사이언시즈, 인코포레이티드 치료 헤테로시클릭 화합물
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
JP7037667B2 (ja) 2017-12-20 2022-03-16 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する３’３’環状ジヌクレオチド
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
EP3814272A4 (de) 2018-05-11 2022-03-02 Phosphorex, Inc. Mikropartikel und nanopartikel mit negativen oberflächenladungen
CN112384505B (zh) 2018-07-06 2025-05-27 吉利德科学公司 治疗性的杂环化合物
AU2019297428C1 (en) 2018-07-06 2023-03-23 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
PE20210642A1 (es) 2018-07-13 2021-03-23 Gilead Sciences Inc Inhibidores de pd-1/pd-l1
EP3860717A1 (de) 2018-10-03 2021-08-11 Gilead Sciences, Inc. Imidozopyrimidinderivate
EP3873608A1 (de) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituierte 6-azabenzimidazolverbindungen mit hpk1-hemmender aktivität
EP4371987B9 (de) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituierte 6-azabenzimidazolverbindungen als hpk1-inhibitoren
WO2020178769A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
CN113574063B (zh) 2019-03-07 2025-03-18 捷克共和国有机化学与生物化学研究所 3’3’-环二核苷酸及其前药
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
WO2020255038A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
CN114245807B (zh) 2019-06-25 2025-05-02 吉利德科学公司 Flt3l-fc融合蛋白和使用方法
PH12022550835A1 (en) 2019-10-18 2023-07-03 Forty Seven Inc Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
NZ786589A (en) 2019-10-31 2025-03-28 Forty Seven Llc Anti-cd47 and anti-cd20 based treatment of blood cancer
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
CN115362003B (zh) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
JP7564888B2 (ja) 2020-05-01 2024-10-09 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３阻害性２，４－ジオキソピリミジン化合物
EP4173639A4 (de) 2020-06-26 2024-03-13 RaQualia Pharma Inc. Verfahren zur auswahl eines krebspatienten mit wirkung einer kombinationstherapie mit retinoid und krebsbehandlungsmittel
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
EP4359413A1 (de) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercolkinase modulierende verbindungen
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
EP4423078A1 (de) 2021-10-28 2024-09-04 Gilead Sciences, Inc. Pyrizidin-3(2h)-on-derivate
PE20241186A1 (es) 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
CA3248911A1 (en) 2022-01-28 2023-08-03 Gilead Sciences, Inc. POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
AU2023240346A1 (en) 2022-03-24 2024-09-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
EP4511127A1 (de) 2022-04-21 2025-02-26 Gilead Sciences, Inc. Kras-g12d-modulierende verbindungen
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
EP4638436A1 (de) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5-inhibitoren und verwendungen davon
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
JP2026522894A (ja) 2023-06-30 2026-07-09 ギリアード サイエンシーズ， インコーポレイテッド Ｋｒａｓ調節化合物
CN121568935A (zh) 2023-07-26 2026-02-24 吉利德科学公司 Parp7抑制剂
AU2024297978A1 (en) 2023-07-26 2026-02-05 Gilead Sciences, Inc. Parp7 inhibitors
EP4774280A1 (de) 2023-09-08 2026-07-15 Gilead Sciences, Inc. Kras-g12d-modulierende verbindungen
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
CN117736980B (zh) * 2024-02-20 2024-05-10 广东先康达生物科技有限公司 脂肪间充质干细胞转化成软骨细胞的诱导分化培养基及其应用
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20260098049A1 (en) 2024-08-12 2026-04-09 Gilead Sciences, Inc. Kras modulating compounds
US20260130893A1 (en) 2024-10-21 2026-05-14 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2026136515A1 (en) 2024-12-19 2026-06-25 Gilead Sciences, Inc. Parp7 inhibitors

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4192869A (en) * 1977-09-06 1980-03-11 Studiengesellschaft Kohle Mbh. Controlled improvement of the O2 release by intact erythrocytes with lipid vesicles
DE2740053A1 (de) * 1977-09-06 1979-05-03 Klaus Prof Dr Med Gersonde Verwendung von allosterischen effektoren mit hilfe von lipidvesikeln ueber eine irreversible inkorporierung zwecks verbesserter o tief 2 -entladung des haemoglobins in erythrozyten
JPS5828878B2 (ja) * 1980-08-20 1983-06-18 三金工業株式会社 環状ピロ燐酸エステル誘導体
US4473496A (en) * 1981-09-14 1984-09-25 The United States Of America As Represented By The Secretary Of The Army Intramolecularly crosslinked hemoglobin
FR2529463B1 (fr) * 1982-07-05 1986-01-10 Centre Nat Rech Scient Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus
US4478824A (en) * 1983-08-08 1984-10-23 Franco Robert S Method for altering red blood cell function and survival
GB8328917D0 (en) * 1983-10-28 1983-11-30 Fisons Plc Blood substitute
US5330979A (en) * 1984-10-23 1994-07-19 Perstorp Ab Method of treating renal disorders with inositoltriphosphate
US5023248A (en) * 1984-10-23 1991-06-11 Perstorp Ab Method of treating diabetes with inositol triphosphate
US5545632A (en) * 1984-10-23 1996-08-13 Perstorp Ab Method of treating retroviral disease
US5407924A (en) * 1984-10-23 1995-04-18 Perstorp Ab Method of treating pain using inositol triphosphate
SE465305B (sv) * 1986-04-16 1991-08-26 Perstorp Ab Anvaendning av inositolfosfat foer framstaellning av ett laekemedel
SE465951B (sv) * 1984-10-23 1991-11-25 Perstorp Ab Isomer av inositoltrifosfat foeretraedesvis i saltform foer anvaendning som terapeutiskt eller profylaktiskt medel samt kompositioner daerav
US5015634A (en) * 1986-04-16 1991-05-14 Perstorp Ab Method of treating tissue damage with inositol triphosphate
US4887995A (en) * 1985-01-22 1989-12-19 University Of Pittsburgh Method of treating sickle cell anemia
US5292913A (en) * 1986-03-11 1994-03-08 Mitsui Toatsu Chemicals, Incorporated Myoinositol derivatives and preparation process thereof
DE3783694T2 (de) * 1986-03-11 1993-05-19 Mitsui Toatsu Chemicals Verfahren zur herstellung von myoinositolabkoemmlingen.
US4699926A (en) * 1986-04-04 1987-10-13 Merck & Co., Inc. Compounds useful in treating sickle cell anemia
US4731381A (en) * 1986-04-04 1988-03-15 Merck & Co., Inc. Method of treating a person for sickle cell anemia
US4731473A (en) * 1986-04-04 1988-03-15 Merck & Co., Inc. Compounds useful in treating sickle cell anemia
US4751244A (en) * 1986-04-04 1988-06-14 Merck & Co., Inc. Compounds useful in treating sickle cell anemia
US5057507A (en) * 1986-04-16 1991-10-15 Perstorp Ab Method of alleviating bone damage with inositoltriphosphate
US5135923A (en) * 1986-04-16 1992-08-04 Perstorp Ab Method of treating cardiovascular diseases
US4952396A (en) * 1986-11-19 1990-08-28 Linus Pauling Institute Of Science & Medicine Method of using phytic acid for inhibiting tumor growth
US5274161A (en) * 1986-11-26 1993-12-28 Perstorp Ab Derivatives of cyclohexane
US4847082A (en) * 1987-01-21 1989-07-11 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
US4873355A (en) * 1987-05-29 1989-10-10 E. I. Du Pont De Nemours And Company Process for regioselectively preparing phosphorylated inositols and other cyclitols
US4924023A (en) * 1987-05-29 1990-05-08 E. I. Du Pont De Nemours And Company Phosphorylated inositols
US4931276A (en) * 1987-10-30 1990-06-05 Franco Robert S Method for introducing desired agents into red blood cells
US4826675A (en) * 1988-02-17 1989-05-02 Colgate-Palmolive Company Anticalculus oral composition
US5043261A (en) * 1989-04-10 1991-08-27 Cryopharm Corporation Lyophilized and reconstituted red blood cell and hemosome compositions
US5082833A (en) * 1988-06-30 1992-01-21 Shamsuddin Abulkalam M Reduction of cell proliferation and enhancement of nk-cell activity
US4874690A (en) * 1988-08-26 1989-10-17 Cryopharm Corporation Lyophilization of red blood cells
US5521087A (en) * 1989-05-10 1996-05-28 Massachusetts Institute Of Technology Method for producing oriented connective tissue cells in a ligament configuration
EP0431197A4 (en) * 1989-06-28 1991-12-04 Mitsui Toatsu Chemicals Inc. Myoinositol derivative and method of production thereof, and phosphorylating agent and its use
US5151539A (en) * 1989-07-03 1992-09-29 Akzo America Inc. Formation of tetraarylpyrophosphate
US5252707A (en) * 1989-09-22 1993-10-12 Mitsui Toatsu Chemicals Incorporated Inositol derivative and method for preparing same
JPH03115290A (ja) * 1989-09-28 1991-05-16 Yokohama Rubber Co Ltd:The １ｄ―ミオイノシトール―１―リン酸の合成法
US5173426A (en) * 1989-10-06 1992-12-22 Yale University DNAs encoding genetically engineered low oxygen affinity mutants of human hemoglobin
US5210263A (en) * 1990-05-15 1993-05-11 University Of Pittsburgh Inositol phosphate analogs and methods for their use
US5295944A (en) * 1991-05-14 1994-03-22 Dana-Farber Cancer Institute Method for treating a tumor with ionizing radiation
US5260472A (en) * 1992-01-29 1993-11-09 The Board Of Governors For Higher Education State Of Rhode Island And Providence Plantations Efficient chemoenzymatic synthesis of D-myo-inositol 1,4,5-triphosphate, D-myo-inositol 1,3,4-triphosphate, and D-myo-inositol 1,3,4,5-tetraphosphate
US5296466A (en) * 1992-02-19 1994-03-22 Board Of Regents, The University Of Texas System Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein
US5344393A (en) * 1992-02-28 1994-09-06 Alliance Pharmaceutical Corp. Use of synthetic oxygen carriers to facilitate oxygen delivery
US5260287A (en) * 1992-05-11 1993-11-09 Board Of Regents, The University Of Texas System Polyphosphorylated organic compounds: compositions useful in protecting biological tissues
ATE272311T1 (de) * 1993-03-23 2004-08-15 Cbr Lab Inc Verfahren und vorrichtung zur einkapselung biologisch aktiver substanzen in zellen
US5866548A (en) * 1993-04-09 1999-02-02 The Regents Of The University Of California Caged membrane-permeant inositol phosphates
WO1995005830A1 (en) * 1993-08-20 1995-03-02 The Regents Of The University Of California Polyanion anti-inflammatory agents
SE503122C2 (sv) * 1993-11-22 1996-03-25 Perstorp Ab Användning av en inositoltrisfosfatester för behandling av inflammatoriska tillstånd
SE502989C2 (sv) * 1993-11-22 1996-03-04 Perstorp Ab Användning av en inositoltrisfosfatester för beredning av läkemedel
JP3543869B2 (ja) * 1995-03-07 2004-07-21 株式会社メニコン 培養皮膚およびその製造法
US5720921A (en) * 1995-03-10 1998-02-24 Entremed, Inc. Flow electroporation chamber and method
US6074605A (en) * 1995-03-10 2000-06-13 Entremed, Inc. Flow electroporation chamber and method
US5626884A (en) * 1995-08-18 1997-05-06 Lockett; Curtis G. Treatment of sickle cell disease
JP3270322B2 (ja) * 1996-02-22 2002-04-02 三菱化学株式会社 金型汚染性の改良された熱可塑性樹脂組成物
FR2749759B1 (fr) * 1996-06-17 1999-11-26 Adir Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose
US6949517B1 (en) * 1996-06-24 2005-09-27 Matti Siren Method of treating inflammatory, tissue repair and infectious conditions
US5977078A (en) * 1996-09-20 1999-11-02 The Regents Of The Univesity Of California Inositol polyphosphate derivatives and methods of using same
DE19649350A1 (de) * 1996-11-28 1998-06-04 Hoechst Ag Inositolglykane mit insulinartiger Wirkung
US6096916A (en) * 1997-05-23 2000-08-01 Nutrimed Biotech Synthesis of D-3 phosphorylated phosphoinositides and analogues
US6187335B1 (en) * 1997-12-31 2001-02-13 Orasomal Technologies, Inc. Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom
BR9915476A (pt) * 1998-11-19 2002-01-02 Organogenesis Inc Construtos de tecidos feitos por bioengenharia e métodos para a sua produção e utilização
US6197061B1 (en) * 1999-03-01 2001-03-06 Koichi Masuda In vitro production of transplantable cartilage tissue cohesive cartilage produced thereby, and method for the surgical repair of cartilage damage
ES2233630T3 (es) * 2000-04-12 2005-06-16 Bitop Aktiengesellschaft Fur Biotechnische Optimierung Uso de solutos compatibles como sustancias con propiedades barredoras de radicales.
US7084126B1 (en) * 2000-05-01 2006-08-01 Healthpartners Research Foundation Methods and compositions for enhancing cellular function through protection of tissue components
WO2002010177A1 (en) * 2000-08-01 2002-02-07 Gmp Companies, Inc. Ammonium salts of inositol hexaphosphate and uses thereof
WO2002009723A2 (en) * 2000-08-01 2002-02-07 Gmp Companies, Inc. Ammonium salts of hemoglobin allosteric effectors, and uses thereof
AU2002217808A1 (en) * 2000-11-21 2002-06-03 Inologic, Inc. Inositol derivatives for increasing chloride secretion and inhibiting inflammation
JP3658316B2 (ja) * 2000-12-19 2005-06-08 株式会社日立製作所 冷却方法および冷却システムならびに情報処理装置
US20030017150A1 (en) * 2001-03-14 2003-01-23 Torphy Theodore J. Chronic obstructive pulmonary disease-related immunglobulin derived proteins, compositions, methods and uses
AU2002327006A1 (en) * 2001-09-20 2003-04-01 Inologic, Inc. Method of modulating sodium ion absorption in epithelial cells
WO2003092700A1 (en) * 2002-04-29 2003-11-13 Gmp Oxycell, Inc. Inositol pyrophosphates, and methods of use thereof
EP1628984A1 (de) * 2003-03-27 2006-03-01 Inologic, Inc. Camphanyliden- und phenylalkylinositolpolyphosphatverbindungen, zusammensetzungen und verfahren zu deren anwendung
ES2232302B1 (es) * 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
US20060106000A1 (en) * 2004-07-06 2006-05-18 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
US20070135389A1 (en) * 2004-07-06 2007-06-14 Claude Nicolau Tumor eradication by inositol-tripyrophosphate
US7745423B2 (en) * 2004-07-06 2010-06-29 NormOxys, Inc Calcium/sodium salt of inositol tripyrophosphate as an allosteric effector of hemoglobin
US20060258626A1 (en) * 2004-07-06 2006-11-16 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
WO2006102060A1 (en) * 2005-03-18 2006-09-28 Oxyplus, Inc. Calcium salt of myo-inositol 1,6:2,3:4,5 tripyrophosphate as an allosteric effector of hemoglobin

Also Published As

Publication number Publication date
FR2828206B1 (fr) 2004-09-24
FR2828206A1 (fr) 2003-02-07
DE60238058D1 (de) 2010-12-02
JP4733346B2 (ja) 2011-07-27
US20040248871A1 (en) 2004-12-09
EP1412484A1 (de) 2004-04-28
CA2456271A1 (fr) 2003-02-20
WO2003014333A1 (fr) 2003-02-20
ES2351875T3 (es) 2011-02-11
EP1412484B1 (de) 2010-10-20
JP2004537998A (ja) 2004-12-24
CA2456271C (fr) 2013-01-08

Similar Documents

Publication Publication Date Title
DE60238058D1 (de) Verwendung von lysyloxydase inhibitoren zur zellkultur und gewebeaufbau
ATE414089T1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
DE60043229D1 (de) Zusammensetzung zur gefässbeschichtung
BR0214029A (pt) Métodos e composições para o uso de células estromais para suportar células tronco embriÈnicas e adultas
ATE407138T1 (de) Verfahren zur herstellung interferierender rna- moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
WO2003080801A3 (en) Adipose stromal stem cells for tissue and vascular modification
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
AU2002221007A1 (en) Suturing instrument and method
CY1111386T1 (el) Ενωσεις και μεθοδοι για αυξηση νευρογενεσης
ATE313634T1 (de) Verfahren zur herstellung von rekombinanten proteinen mittels inhibitoren von apoptose
ATE540129T1 (de) Target zur therapie kognitiver behinderungen
ATE295735T1 (de) Verwendung von interleukin-6 antagonisten zur behandlung von oestrogen-abhängigen krebs
TR200103216T2 (tr) Pirimidinon bileşimleri
BRPI0410467A (pt) composições e métodos para tratamento de sìndrome respiratória aguda severa (sars)
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
FI20020176A0 (fi) Menetelmõ ja reagenssipakkaus geneettisen yhtõlõisyyden osoittamiseksi
ATE394124T1 (de) Verfahren, zusammensetzungen und herstellungsgegenstände zur modulierung des knochenwachstums
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
TW200508233A (en) Chk-1 inhibitors
ATE507209T1 (de) Referenzstandard zur charakterisierung von rosuvastatin
DE60218153D1 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
IS7154A (is) Bv8 kjarnsýrur og fjölpeptíð með mítósu-valdandi verkun
NO20061138L (no) Gjaercellevegger for behandling eller forebygging av hyperglukemi eller for a stabilisere glukemi
DE60327710D1 (de) Modifizierte zytokine für krebs therapie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties